Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
ReproCELL, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
4978 ReproCELL Incorporated 【J-GAAP】
Earnings ReportReproCELL Incorporated <4978> [TSE Growth] announced its financial results after the market closed on February 12th (15:30). The consolidated ordinary loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) expanded to a loss of 455 million yen (compared to a loss of 33 million yen in the same period last year).
In addition, the full-year forecast for consolidated ordinary profit/loss has been revised downward from an expected loss of 75 million yen to a loss of 574 million yen (compared to a profit of 45 million yen in the previous period), indicating an expansion in the loss margin.
Based on the full-year plan announced by the company after the downward revision, our estimate of the consolidated ordinary profit/loss for the October to March period (second half) has been revised downward from an expected profit of 408 million yen to a loss of 91 million yen (compared to a profit of 148 million yen in the same period of the previous year), turning to a loss outlook.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit significantly dropped to 28 million yen, a 60.0% decrease compared to the same period last year. The operating profit/loss margin drastically worsened from -4.1% in the same period last year to -20.5%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 1,776 | -289 | 58 | 48 | 0.6 | 145.0 | Feb 9, 2024 | J-GAAP |
| Apr - Dec, 2024 | 2,068 | -180 | -33 | -31 | -0.3 | ー | Feb 13, 2025 | J-GAAP |
| Apr - Dec, 2025 | 1,609 | -676 | -455 | -458 | -4.9 | ー | Feb 12, 2026 | J-GAAP |
| YoY | -22.2% | -275.6% | -1,278.8% | -1,377.4% | -1,326.5% |
Guidance Update
Second Half Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2025 Prev | 2,063 | 278 | 408 | 411 | 4.3 | 0 | Nov 13, 2025 | J-GAAP |
| Oct - Mar, 2025 New | 1,302 | -298 | -91 | -89 | -0.9 | 0 | Feb 12, 2026 | J-GAAP |
| Revision Rate | -36.9% | - | - | - | - |
Full Year Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2026 Prev | 3,037 | -268 | -75 | -75 | -0.8 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 New | 2,276 | -844 | -574 | -575 | -6.1 | 0 | Feb 12, 2026 | J-GAAP |
| Revision Rate | -25.1% | -214.9% | -665.3% | -666.7% | -668.4% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 1,658 | 19 | 148 | 207 | 2.2 | 0 | May 14, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 1,302 | -298 | -91 | -89 | -0.9 | 0 | Feb 12, 2026 | J-GAAP |
| YoY | -21.5% | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 2,426 | -409 | 40 | -31 | -0.4 | 0 | May 13, 2024 | J-GAAP |
| Mar, 2025 | 2,978 | -130 | 45 | 103 | 1.1 | 0 | May 14, 2025 | J-GAAP |
| Mar, 2026 Guidance | 2,276 | -844 | -574 | -575 | -6.1 | 0 | Feb 12, 2026 | J-GAAP |
| YoY | -23.6% | -549.2% | - | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 748 | -31 | 70 | 73 | 0.8 | -4.1 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 910 | 50 | 78 | 134 | 1.4 | 5.5 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 475 | -291 | -301 | -304 | -3.2 | -61.3 | Aug 13, 2025 | J-GAAP |
| Jul - Sep, 2025 | 499 | -255 | -182 | -182 | -1.9 | -51.1 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 635 | -130 | 28 | 28 | 0.3 | -20.5 | Feb 12, 2026 | J-GAAP |
| YoY | -15.1% | -319.4% | -60.0% | -61.6% | -62.5% |
Related Articles
en Japan, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 12%, Exceeds Full-Year Plan
Fuso Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 34%, Oct-Dec Ordinary Profit Decreases by 9%
WASHINGTON HOTEL, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 31%, Dividend Revised Upward by 14 Yen
SD ENTERTAINMENT, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Loss, Oct-Dec Ordinary Profit Turns to Loss
CyberBuzz, Oct-Dec (1Q) Ordinary Profit Increases by 50%
Monex Group, Apr-Dec (Cumulative 3Q) Net Income Turns to Profit, Oct-Dec Net Income Turns to Profit
ROHTO PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 6%, Exceeded Record Profit Forecast, Dividend Revised Upward by 1 Yen
CRI Middleware, Oct-Dec (1Q) Ordinary Profit Decreases by 74%
ExaWizards, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Profit, Oct-Dec Ordinary Profit Increases by 237 times
Human Metabolome Tech, First Half Ordinary Profit Decreases by 50%